Growth inhibitory and bactericidal efficacy of sera from Lyme borreliosis patients on B. burgdorferi strains.
Two B. afzelii strains EB1 and FEM1, classified in normal human sera (NHS) as serum-resistant, and an intermediate serum-sensitive B. burgdorferi s.s. strain 297, were tested in regard of their serum sensitivity in immune sera (IS) of patients at all stages of Lyme borreliosis by a growth inhibition assay (GIA). Fifty-four per cent (13/24) of the tested IS were GIA positive, while the sera of patients in stage III disease inhibited the growth more frequently than did the patients with sera of stage II or stage I disease. Growth inhibition was predominantly directed against strain FEM1 (12/24), less against strain EB1 (4/24) and strain 297 (2/24). A growth inhibiting effect on two strains was only detectable for two IS and merely one stage III serum inhibited all three strains. Positive results in the GIA required fresh serum and resulted in the killing of the borreliae. The detection of the deposited complement components C3 and C9 on the surfaces of the inhibited strains by means of immunofluorescence assays confirmed the role of complement. In Westernblot analyses of strain FEM1, it was striking that GIA-positive IS reacted 3- to 5-fold more often with proteins of molecular masses of 48.9-, 38.6-, 27.5-, 25-, 23.1- (OspC), 21.7-, and 16-kDa, than did GIA-negative IS. Furthermore, two proteins of approximately 20- and 31.2-kDa reacted exclusively with GIA-positive IS. Antibodies reacting with these proteins could play a role in the growth inhibition of NHS-resistant borrelial strains, OspC.
Kraiczy
P
P
Medical Microbiology, University of Frankfurt, Federal Republic of Germany. Kraiczy@em.uni-frankfurt.de
Peters
S
S
Seitz
C
C
Würzner
R
R
Oschmann
P
P
Brade
V
V
D000942:Antigens, Bacterial / Q000378:metabolism; D001770:Blood Bactericidal Activity / Q000502:physiology*; D015748:Borrelia burgdorferi Group / Q000254:growth & development* / Q000276:immunology / Q000502:physiology*; D003176:Complement C3 / Q000378:metabolism; D003186:Complement C9 / Q000378:metabolism; D006801:Humans; D007106:Immune Sera / Q000494:pharmacology*; D008193:Lyme Disease / Q000097:blood / Q000276:immunology / Q000382:microbiology*
D000942:Antigens, Bacterial; D003176:Complement C3; D003186:Complement C9; D007106:Immune Sera